Thank you, Gary, and good morning, everyone. Before commenting on our financial results in the quarter, I would like to say a few words regarding the implementation of LDTI. Yesterday, we posted our fourth quarter 2022 financial supplement recast to reflect the adoption of the new accounting standard. The impact on the balance sheet of transition and on earnings over the re-measurement period were in-line with the estimates we had previously provided. As a reminder, LDTI has no impact on stat’s financial results, capital or cash flows. I would like to second Gary’s comment from the beginning of the call and also expressed my gratitude to the CNO implementation team. We are well-positioned not just for the first quarter close under the new standard, but also to operate smoothly and efficiently going forward. Turning to the financial highlights on Slide 8. Our net income for the quarter was a loss of just under $1 million, driven by a non-operating loss of $59 million, which in turn was driven primarily by $65 million pretax of fair value changes, embedded derivative, reserve liabilities and market risk benefits, both of which relate to the GAAP accounting for our annuity business and both of which are largely non-economic in nature. Conversely, our operating income for the quarter was a gain of $59 million or $0.51 per share, $6 million or $0.03 per share lower than the prior year period, driven by a decline in the variable components of net investment income. Expenses were also elevated compared to the prior year period, but in-line with our expectations for the quarter. Our projected expense ratio for the full-year is unchanged at between 19.0% and 19.4%. On a run rate basis, we are very pleased with the results in the quarter. Notably, insurance product margin increased by $14 million or 7% year-over-year, and fee income increased by $6 million or 57%. We deployed $15 million of capital on share repurchases in the quarter contributing to a 5% reduction in weighted average diluted shares outstanding year-over-year. For the 12-months ending March 31, 2023, operating return on equity was 10.3%. Turning to Slide 9, the growth and insurance product margin was driven by growth in lower mortality by growth and lower mortality in the Life business, and also reflects growth in fixed indexed annuities and supplemental health. The annuity and health margins were largely flat in total year-over-year, with pluses and minuses by individual product line within each product category. Turning to Slide 10. The new money rate in the quarter was 6.34%, up from 3.73% in the prior year period, and 5.96% in 4Q 2022. This is the fourth consecutive quarter with new money rates exceeding the average yield unallocated investments, which increased to 4.62% in the quarter, up two basis points both sequentially and year-over-year. This marks the third quarter of sequential improvement, and the first quarter of year-over-year improvement in net yield. While the improvement is small, it is nevertheless an important inflection point after years of declining yield, and together with growth in net insurance liabilities, contributes to growth in net investment income allocated to product, which was up 4% in the quarter. Investment income not allocated to products fell in the quarter, driven by a decline in the return on alternative investments and also a decline in prepayment and call income. Notably, the decline was in part mitigated by growth and income from general account assets, the FHLB and FABN programs and the contribution from quarterly investments. Our new investments comprised approximately $690 million of assets, with an average rating of AA- and an average duration of three-years. Our new investments are summarized in more detail on slides 21 and 22 of this presentation. Turning to Slide 11. At quarter end, our invested assets totaled $25 billion, down 8% year-over-year, reflecting declining market values driven primarily by higher interest rates. Approximately 97% of our fixed maturity portfolio at quarter end was investment grade rated with an average rating of single A reflecting our up and quality actions over the last several quarters. In the last 12-months. The allocation to single A rated or higher securities is up 460 basis points. The BBB allocation is down 330 basis points, and the high yield allocation is down 130 basis points. These actions served as well during the recent banking crisis and continue to position as well relative to potential broader economic downturn. Given the amount of attention that commercial real estate market has received in the media and an equity research recently, I thought, I should touch on that briefly. You will note that 9.8% of our investment assets are in commercial mortgage backed securities, and 4.7% are in commercial mortgage loans. We have included some metrics on these investments in Slides 23 and 24 of this presentation. The key messages are number one that our CMBS allocation is highly rated with significant structural protection tilted toward lower risk property types and with limited loss content in extreme stress scenarios. And second, that our commercial mortgage loan allocation is also conservatively positioned across a number of metrics. Turning to Slide 12. At quarter end, our consolidated RBC ratio is 380%, Holdco liquidity was $158 million. We continue to manage this to the targets of 375% RBC, and $150 million Holdco liquidity. Turning to Slide 13. Our outlook for the full-year as summarized on this slide is unchanged from what we shared back in February at our Investor Day. I do want to provide an update on our plan formation of a captive Bermuda Reinsurance Company. We continue to work through the regulatory approval process, which we expect will conclude in time to initiate a treaty in the third quarter of this year. Under this treaty, we intend to cede a portion of our fixed index annuity business, from our U.S. operations to the Bermuda Company. Contingent on all necessary regulatory approvals, we expect excess cash flow to the Holdco to increase by $150 million to $200 million at inception of the initial reinsurance treaty. We will certainly be judicious in how and when we deploy that capital, applying the same discipline and logic that we have historically. Regulatory approval is by no means assured, and we don’t want to get ahead of the approval process. But we thought it was nevertheless appropriate at this stage to dimensionalize what the capital impact might be. And with that, I will turn it back to Gary.